Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is
expressed in several types of tumors. That fact, together with the role of HER3 in promoting …

The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been
major threats to people's health. With the identification of carcinogenic drivers in non-small …

Engineering approaches using antibody drug conjugates (ADCs) and bispecific antibodies
(bsAbs) are designed to overcome the limitations of conventional chemotherapies and …

Recent progressions in immunotherapy have transformed cancer treatment, providing a
promising strategy that activates the immune system of the patient to find and eliminate …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is the most common type of
pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading …

Antibody-based cancer immunotherapy has become a powerful asset in the arsenal against
malignancies. In this regard, bispecific antibodies (BsAbs) are a ground-breaking novel …

Lung cancer remains the leading cause of cancer-associated mortality worldwide, but with
the emergence of oncogene targeted therapies, treatment options have tremendously …